HSV therapy and HIV-1 reduction [1]

New England Journal of Medicine

Volumn 356, Issue 22, 2007, Pages 2323-2324

  Martinez, Valérie ^a   Caumes, Eric ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CIDOFOVIR; FOSCARNET; VALACICLOVIR; ANTIVIRUS AGENT; DRUG DERIVATIVE; VALINE; VIRUS RNA;

DEVELOPING COUNTRY; DISEASE ASSOCIATION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LETTER; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS RESISTANCE; DRUG EFFECT; NOTE; PHYSIOLOGY; VIRUS LOAD; VIRUS REPLICATION; ANTIBIOTIC RESISTANCE; BLOOD;

ACYCLOVIR; ANTIVIRAL AGENTS; HERPES SIMPLEX; HIV INFECTIONS; HIV-1; HUMANS; RNA, VIRAL; VALINE; VIRAL LOAD; VIRUS REPLICATION; DRUG RESISTANCE, VIRAL; HERPESVIRUS 2, HUMAN;

EID: 34249797305     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc076120     Document Type: Letter

References (3)

1. Nagot N, Ouédraogo A, Foulongne V, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007;356:790-9.
2. DeJesus A, Wald T, Warren T, et al. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. J Infect Dis 2003;188:1009-16. [Erratum, J Infect Dis 2003;188:1404.]
3. Tyring SK, Baker D, Snowden W. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir. J Infect Dis 2002;186:Suppl 1:S40-S46.